Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2013

Open Access 01-12-2013 | Research

Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry

Authors: Zhiyuan Wen, Bolin Zhao, Kun Song, Xule Hu, Weiye Chen, Dongni Kong, Jinying Ge, Zhigao Bu

Published in: Virology Journal | Issue 1/2013

Login to get access

Abstract

Background

Using reverse genetics, we generated a recombinant low-pathogenic LaSota strain Newcastle disease virus (NDV) expressing the glycoprotein (GP) of Ebola virus (EBOV), designated rLa-EBOVGP, and evaluated its biological characteristic in vivo and in vitro.

Results

The introduction and expression of the EBOV GP gene did not increase the virulence of the NDV vector in poultry or mice. EBOV GP was incorporated into the particle of the vector virus and the recombinant virus rLa-EBOVGP infected cells and spread within them independently of exogenous trypsin. rLa-EBOVGP is more resistant to NDV antiserum than the vector NDV and is moderately sensitive to EBOV GP antiserum. More importantly, infection with rLa-EBOVGP was markedly inhibited by IPA3, indicating that rLa-EBOVGP uses macropinocytosis as the major internalization pathway for cell entry.

Conclusions

The results demonstrate that EBOV GP in recombinant NDV particles functions independently to mediate the viral infection of the host cells and alters the cell-entry pathway.
Appendix
Available only for authorised users
Literature
1.
2.
Hoenen T, Groseth A, Falzarano D, Feldmann H: Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med. 2006, 12: 206-215. 10.1016/j.molmed.2006.03.006.PubMedCrossRef
3.
Feldmann H, Klenk HD, Sanchez A: Molecular biology and evolution of filoviruses. Arch Virol Suppl. 1993, 7: 81-100. 10.1007/978-3-7091-9300-6_8.PubMedCrossRef
4.
Chan SY, Speck RF, Ma MC, Goldsmith MA: Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol. 2000, 74: 4933-4937. 10.1128/JVI.74.10.4933-4937.2000.PubMedPubMedCentralCrossRef
5.
Ito H, Watanabe S, Sanchez A, Whitt MA, Kawaoka Y: Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol. 1999, 73: 8907-8912.PubMedPubMedCentral
6.
Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y: A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA. 1997, 94: 14764-14769. 10.1073/pnas.94.26.14764.PubMedPubMedCentralCrossRef
7.
Wool-Lewis RJ, Bates P: Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol. 1998, 72: 3155-3160.PubMedPubMedCentral
8.
Yang Z, Delgado R, Xu L, Todd RF, Nabel EG, Sanchez A, Nabel GJ: Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science. 1998, 279: 1034-1037. 10.1126/science.279.5353.1034.PubMedCrossRef
9.
Volchkov VE, Volchkova VA, Muhlberger E, Kolesnikova LV, Weik M, Dolnik O, Klenk HD: Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science. 2001, 291: 1965-1969. 10.1126/science.1057269.PubMedCrossRef
10.
Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ: Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med. 2000, 6: 886-889. 10.1038/78645.PubMedCrossRef
11.
Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, Peters CJ, Parren PW, Burton DR: Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 1999, 73: 6024-6030.PubMedPubMedCentral
12.
Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK: Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000, 287: 1664-1666. 10.1126/science.287.5458.1664.PubMedCrossRef
13.
Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, et al: Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006, 3: e177-10.1371/journal.pmed.0030177.PubMedPubMedCentralCrossRef
14.
Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, et al: CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011, 17: 1128-1131. 10.1038/nm.2447.PubMedCrossRef
15.
Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, et al: Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005, 11: 786-790. 10.1038/nm1258.PubMedCrossRef
16.
Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Stroher U, Feldmann H, Jones SM: Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009, 4: e5547-10.1371/journal.pone.0005547.PubMedPubMedCentralCrossRef
17.
DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A: Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine. 2010, 29: 17-25. 10.1016/j.vaccine.2010.10.024.PubMedPubMedCentralCrossRef
18.
Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, et al: Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011, 85: 10605-10616. 10.1128/JVI.00558-11.PubMedPubMedCentralCrossRef
19.
Alexander DJ: Newcastle Disease. 1989, American Association for Avian Pathologists: Kennett Square, PA
20.
Peeters BP, de Leeuw OS, Koch G, Gielkens AL: Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol. 1999, 73: 5001-5009.PubMedPubMedCentral
21.
Panda A, Huang Z, Elankumaran S, Rockemann DD, Samal SK: Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb Pathog. 2004, 36: 1-10. 10.1016/j.micpath.2003.07.003.PubMedCrossRef
22.
Charan S, Mahajan VM, Agarwal LP: Newcastle disease virus antibodies in human sera. Indian J Med Res. 1981, 73: 303-307.PubMed
23.
Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 1999, 6: 63-73. 10.1038/sj.gt.3300787.PubMedCrossRef
24.
Morrison T, McQuain C, Sergel T, McGinnes L, Reitter J: The role of the amino terminus of F1 of the Newcastle disease virus fusion protein in cleavage and fusion. Virology. 1993, 193: 997-1000. 10.1006/viro.1993.1214.PubMedCrossRef
25.
Nagai Y, Klenk HD, Rott R: Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology. 1976, 72: 494-508. 10.1016/0042-6822(76)90178-1.PubMedCrossRef
26.
Alexander D: Newcastle Disease and Other Avian Paramyxoviridae Infections. 1997, Ames: Iowa State University Press
27.
Ge J, Tian G, Zeng X, Jiang Y, Chen H, Bua Z: Generation and evaluation of a Newcastle disease virus-based H9 avian influenza live vaccine. Avian Dis. 2010, 54: 294-296. 10.1637/8731-032509-ResNote.1.PubMedCrossRef
28.
Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, Sagrera A, Villar E, Garcia-Sastre A, Palese P: Recombinant Newcastle disease virus as a vaccine vector. J Virol. 2001, 75: 11868-11873. 10.1128/JVI.75.23.11868-11873.2001.PubMedPubMedCentralCrossRef
29.
DiNapoli JM, Kotelkin A, Yang L, Elankumaran S, Murphy BR, Samal SK, Collins PL, Bukreyev A: Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci USA. 2007, 104: 9788-9793. 10.1073/pnas.0703584104.PubMedPubMedCentralCrossRef
30.
Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M, Murphy BR, Samal SK, Collins PL: Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol. 2005, 79: 13275-13284. 10.1128/JVI.79.21.13275-13284.2005.PubMedPubMedCentralCrossRef
31.
DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H, Torres-Velez F, Murphy BR, Samal SK, Collins PL, Bukreyev A: Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol. 2010, 84: 1489-1503. 10.1128/JVI.01946-09.PubMedPubMedCentralCrossRef
32.
Ge J, Deng G, Wen Z, Tian G, Wang Y, Shi J, Wang X, Li Y, Hu S, Jiang Y, et al: Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol. 2007, 81: 150-158. 10.1128/JVI.01514-06.PubMedPubMedCentralCrossRef
33.
Khattar SK, Samal S, Devico AL, Collins PL, Samal SK: Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol. 2011, 85: 10529-10541. 10.1128/JVI.05050-11.PubMedPubMedCentralCrossRef
34.
Carnero E, Li W, Borderia AV, Moltedo B, Moran T, Garcia-Sastre A: Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol. 2009, 83: 584-597. 10.1128/JVI.01443-08.PubMedPubMedCentralCrossRef
35.
Ge J, Wang X, Tao L, Wen Z, Feng N, Yang S, Xia X, Yang C, Chen H, Bu Z: Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J Virol. 2011, 85: 8241-8252. 10.1128/JVI.00519-11.PubMedPubMedCentralCrossRef
36.
Kong D, Wen Z, Su H, Ge J, Chen W, Wang X, Wu C, Yang C, Chen H, Bu Z: Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Virology. 2012, 432: 327-335. 10.1016/j.virol.2012.06.001.PubMedCrossRef
37.
Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, Moormann RJ: Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine. 2010, 28: 4394-4401. 10.1016/j.vaccine.2010.04.048.PubMedCrossRef
38.
Kortekaas J, Dekker A, de Boer SM, Weerdmeester K, Vloet RP, de Wit AA, Peeters BP, Moormann RJ: Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine. 2010, 28: 2271-2276. 10.1016/j.vaccine.2010.01.001.PubMedCrossRef
39.
Khattar SK, Collins PL, Samal SK: Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine. 2010, 28: 3159-3170. 10.1016/j.vaccine.2010.02.051.PubMedPubMedCentralCrossRef
40.
Bukreyev A, Collins PL: Newcastle disease virus as a vaccine vector for humans. Curr Opin Mol Ther. 2008, 10: 46-55.PubMed
41.
Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O’Neil JD, Groene WS, et al: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002, 20: 2251-2266. 10.1200/JCO.2002.08.042.PubMedCrossRef
42.
Ockert D, Schirrmacher V, Beck N, Stoelben E, Ahlert T, Flechtenmacher J, Hagmuller E, Buchcik R, Nagel M, Saeger HD: Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res. 1996, 2: 21-28.PubMed
43.
Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, Helmke BH, Weidauer H, Schirrmacher V, Herold-Mende C: Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 2004, 64: 8057-8061. 10.1158/0008-5472.CAN-04-1545.PubMedCrossRef
44.
OIE: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2011. 2011, Paris: Office International des Epizooties
45.
Cantin C, Holguera J, Ferreira L, Villar E, Munoz-Barroso I: Newcastle disease virus may enter cells by caveolae-mediated endocytosis. J Gen Virol. 2007, 88: 559-569. 10.1099/vir.0.82150-0.PubMedCrossRef
46.
Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G, Halfmann P, Kawaoka Y: Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 2010, 6: e1001121-10.1371/journal.ppat.1001121.PubMedPubMedCentralCrossRef
47.
Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA: Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 2010, 6: e1001110-10.1371/journal.ppat.1001110.PubMedPubMedCentralCrossRef
48.
Aleksandrowicz P, Marzi A, Biedenkopf N, Beimforde N, Becker S, Hoenen T, Feldmann H, Schnittler HJ: Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J Infect Dis. 2011, 204 (Suppl 3): S957-S967. 10.1093/infdis/jir326.PubMedPubMedCentralCrossRef
49.
50.
Kerr MC, Teasdale RD: Defining macropinocytosis. Traffic. 2009, 10: 364-371. 10.1111/j.1600-0854.2009.00878.x.PubMedCrossRef
51.
Mercer J, Helenius A: Virus entry by macropinocytosis. Nat Cell Biol. 2009, 11: 510-520. 10.1038/ncb0509-510.PubMedCrossRef
52.
Rodal SK, Skretting G, Garred O, Vilhardt F, van Deurs B, Sandvig K: Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell. 1999, 10: 961-974. 10.1091/mbc.10.4.961.PubMedPubMedCentralCrossRef
53.
Subtil A, Gaidarov I, Kobylarz K, Lampson MA, Keen JH, McGraw TE: Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci USA. 1999, 96: 6775-6780. 10.1073/pnas.96.12.6775.PubMedPubMedCentralCrossRef
54.
Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M: Recombinant nipah virus vaccines protect pigs against challenge. J Virol. 2006, 80: 7929-7938. 10.1128/JVI.00263-06.PubMedPubMedCentralCrossRef
55.
Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, Godoy H, et al: Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA. 2012, 109: 5797-5802. 10.1073/pnas.1117208109.PubMedPubMedCentralCrossRef
56.
Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, et al: Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine. 2006, 24: 417-425. 10.1016/j.vaccine.2005.08.041.PubMedCrossRef
57.
Vaccari M, Halwani R, Patterson LJ, Boasso A, Beal J, Tryniszewska E, Hryniewicz A, Venzon D, Haddad EK, El-Far M, et al: Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS. J Virol. 2013, 87: 3526-3537. 10.1128/JVI.02686-12.PubMedPubMedCentralCrossRef
58.
Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P: Newcastle disease virus V protein is a determinant of host range restriction. J Virol. 2003, 77: 9522-9532. 10.1128/JVI.77.17.9522-9532.2003.PubMedPubMedCentralCrossRef
59.
Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF: Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol. 2003, 77: 1501-1511. 10.1128/JVI.77.2.1501-1511.2003.PubMedPubMedCentralCrossRef
60.
Huang Z, Krishnamurthy S, Panda A, Samal SK: Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J Virol. 2003, 77: 8676-8685. 10.1128/JVI.77.16.8676-8685.2003.PubMedPubMedCentralCrossRef
61.
Blach-Olszewska Z: Interferon induction by Newcastle disease virus in mice. Arch Immunol Ther Exp (Warsz). 1970, 18: 418-441.
62.
Brehm G, Kirchner H: Analysis of the interferons induced in mice in vivo and in macrophages in vitro by Newcastle disease virus and by polyinosinic-polycytidylic acid. J Interferon Res. 1986, 6: 21-28. 10.1089/jir.1986.6.21.PubMedCrossRef
63.
Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A: A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol. 2006, 80: 2267-2279. 10.1128/JVI.80.5.2267-2279.2006.PubMedPubMedCentralCrossRef
64.
Kunz S, Rojek JM, Perez M, Spiropoulou CF, Oldstone MB: Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan. J Virol. 2005, 79: 5979-5987. 10.1128/JVI.79.10.5979-5987.2005.PubMedPubMedCentralCrossRef
65.
Ogino M, Ebihara H, Lee BH, Araki K, Lundkvist A, Kawaoka Y, Yoshimatsu K, Arikawa J: Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin Diagn Lab Immunol. 2003, 10: 154-160.PubMedPubMedCentral
66.
Kaku Y, Noguchi A, Marsh GA, McEachern JA, Okutani A, Hotta K, Bazartseren B, Fukushi S, Broder CC, Yamada A, et al: A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. J Virol Methods. 2009, 160: 7-13. 10.1016/j.jviromet.2009.04.037.PubMedCrossRef
67.
Wang X, Ge J, Hu S, Wang Q, Wen Z, Chen H, Bu Z: Efficacy of DNA immunization with F and G protein genes of Nipah virus. Ann N Y Acad Sci. 2006, 1081: 243-245. 10.1196/annals.1373.029.PubMedCrossRef
68.
Fields Virology. Edited by: Lamb RA, Kolakofsky D. 2001, Philadelphia: Lippincott-Williams & Wilkins, 3
69.
Hernandez LD, Hoffman LR, Wolfsberg TG, White JM: Virus-cell and cell-cell fusion. Annu Rev Cell Dev Biol. 1996, 12: 627-661. 10.1146/annurev.cellbio.12.1.627.PubMedCrossRef
70.
Lamb RA: Paramyxovirus fusion: a hypothesis for changes. Virology. 1993, 197: 1-11. 10.1006/viro.1993.1561.PubMedCrossRef
71.
Quinn K, Brindley MA, Weller ML, Kaludov N, Kondratowicz A, Hunt CL, Sinn PL, McCray PB, Stein CS, Davidson BL, et al: Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors. J Virol. 2009, 83: 10176-10186. 10.1128/JVI.00422-09.PubMedPubMedCentralCrossRef
72.
Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, et al: Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011, 477: 340-343. 10.1038/nature10348.PubMedPubMedCentralCrossRef
73.
Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, Ndungo E, Sandesara RG, Carette JE, Kuehne AI, et al: Ebola virus entry requires the host-programmed recognition of an intracellular receptor. Embo J. 2012, 31: 1947-1960. 10.1038/emboj.2012.53.PubMedPubMedCentralCrossRef
Metadata
Title
Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry
Authors
Zhiyuan Wen
Bolin Zhao
Kun Song
Xule Hu
Weiye Chen
Dongni Kong
Jinying Ge
Zhigao Bu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2013
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-10-331

Other articles of this Issue 1/2013

Virology Journal 1/2013 Go to the issue

Research

Pathogenic characteristics of three genotype II porcine reproductive and respiratory syndrome viruses isolated from China

Research

Prevalence of HCV among the young male blood donors of Quetta region of Balochistan, Pakistan

Research

Genetic diversity of Newcastle disease virus in Pakistan: a countrywide perspective

Short report

Posttranslational modifications and secretion efficiency of immunogenic hepatitis B virus L protein deletion variants

Research

TH1 cytokine response to HCV peptides in Egyptian health care workers: a pilot study

Short report

Development and characterization of the replicon system of Japanese encephalitis live vaccine virus SA14-14-2
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits